Ajona et al. [89], tested the anti-tumor efficacy of the combination of an anti-programmed cell death protein 1 (PD-1) mAb and an anti-C5a spiegelmer (a L-stereoisomer aptamer, highly stable because of its non-natural conformation) in preclinical lung cancer models. Here, PDCD1 is linked to lung carcinoma.